MCHM Macrochem (MM)

MacroChem to Present at Drug Delivery Global Summit- Evaluating Emerging Technologies in London LEXINGTON, Mass. and LONDON, Oct. 6 /PRNewswire-FirstCall/ -- MacroChem Corporation (NASDAQ:MCHM) has announced that Thomas Chan, PhD, Vice President, Research & Development and Chief Technology Officer, will present at the Drug Delivery Global Summit - Evaluating Emerging Technologies tomorrow in London. The annual conference is attended by management from pharmaceutical companies from Europe, North America and the Far East. In his London address, Dr. Chan will discuss chemically enhanced transdermal drug delivery as part of the conference focus on "Innovative Methods of Drug Delivery." He will explain the rationale for transdermal delivery of pharmaceuticals, and techniques of physical and chemical enhancement, focusing on MacroChem's proprietary "soft enhancement of percutaneous penetration" (SEPA(R)) technology. Dr. Chan will review the company's SEPA-enhanced products in clinical development - Opterone(R), a topical testosterone cream for treating male hypogonadism, and EcoNail(TM), an econazole nail lacquer for treating fungal nail infections. "Traditionally, the transdermal delivery of drugs has been limited to potent, lipophilic molecules because the majority of pharmaceuticals do not penetrate the skin in significant amounts," said Dr. Chan. "Chemical skin enhancers such as MacroChem's SEPA 0009 (2-n-nonyl-1, 3- dioxolane) have been shown to promote transdermal absorption of a wide variety of active pharmaceutical ingredients in topical formulations," he said. About MacroChem MacroChem is a specialty pharmaceutical company that develops and seeks to commercialize topically delivered pharmaceuticals employing SEPA(R), the company's proprietary absorption-enhancement technology. SEPA(R) is a series of proprietary dioxolanes and dioxanes that transiently fluidize the lipids in the stratum corneum and increase molecular diffusion across this barrier. SEPA -- either alone or in combination with one of five different pharmaceuticals -- has been tested in 48 human studies involving more than 4,000 participants, For further information please consult http://www.macrochem.com/. Forward-Looking Statements With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Bernard Patriacca - VP/CFO (781) 862-4003 Media Contact: Donna LaVoie (LaVoie Group) (781) 596-0200 x103 DATASOURCE: MacroChem Corporation CONTACT: Investor, Bernard Patriacca - VP/CFO of MacroChem, +1-781-862-4003, or Media, Donna LaVoie of LaVoie Group, +1-781-596-0200, ext. 103 for MacroChem Web site: http://www.macrochem.com/

Copyright